-
Salubris Taifawei, Class 1 new drugs rush to the 25 billion market
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];On November 22, Salubris announced that the clinical trial application of SAL0119 tablets, an innovative small molecule drug independently developed by the company, was accepted, and the clinical indications currently planned to be developed include active ankylosing spondylitis and moderate to severe active rheumatoid arthritis.
-
21 Chinese medicine pieces joint mining sprint! The 200 billion market welcomes the reshuffle
Time of Update: 2023-01-01
Data statistics as of November 30, if there is any omission, welcome to correct!The latest news said that the first batch of joint procurement of traditional Chinese medicine pieces in the country has entered the stage of enterprise quotation, and the results of bid opening will be just around the corner.
-
Heisco is powerful! 16 innovative drugs are eye-catching, aiming at 300 billion markets
Time of Update: 2023-01-01
Recently, the research and development of Haisco innovative drugs has made new progress, HSK16149 capsules have been declared for marketing, and the phase II clinical trial of HSK31858 tablets has been ethically approved.
-
The pharmaceutical business sector has soared again! Liuyao Group touched the limit of increase, and Jianzhijia rose more than 5%
Time of Update: 2023-01-01
From the perspective of individual stocks, Liuyao Group touched the price limit, Jianzhijia rose by more than 5%, Yixintang, People's Tongtai, *ST Bikang, First Pharmaceutical, Laomin, Yifeng Pharmacy, etc.
-
In the 100 billion small molecule drug market, the innovation of domestic pharmaceutical companies has begun to enter the harvest period
Time of Update: 2023-01-01
In addition, in early November, Ascletis also announced that ASC61, an oral small molecule inhibitor of PD-L1 independently developed by the company, was approved by the National Medical Products Administration of China (NMPA) to carry out a new drug clinical trial (IND) application for the treatment of advanced solid tumors.
-
In 2023, there will be 4 major trends in the domestic pharmaceutical industry
Time of Update: 2023-01-01
Looking forward to 2023, the author has sorted out four major development trends in the pharmaceutical industry from the perspective of observers: "cost control" is still the main line of pharmaceutical industry policy, domestic substitution is accelerating under the trend of new medical infrastructure, new drug research and development pays more attention to clinical value, and the traditional Chinese medicine industry continues to expand, for industry reference only.
-
The number of people vaccinated with the third dose of the new crown vaccine in Japan accounts for 66.9% of the total population of the country
Time of Update: 2023-01-01
(End) According to the Japan Broadcasting Association TV, the latest data released by the Japanese government on the 28th shows that the number of people in Japan who have completed the third dose of the new crown vaccine is 84241169, accounting for 66.
-
The country talks about the "last mile" of drugs entering the hospital, and large hospitals also have bitterness
Time of Update: 2023-01-01
Since 2018, with the normalization of the national negotiation and access mechanism for drugs, more than 500 new drugs have been included in the medical insurance catalogue through negotiation and price reduction in the past five years.
-
The total number of direct settlements for medical treatment across provinces has exceeded 50 million
Time of Update: 2023-01-01
ntenteditable="false" style="border-top:1px dashed rgb(255, 0, 0); color:rgb(255, 255, 255); display:block; font-size:0px; height:0px; left:0px; line-height:0px; margin:0px; padding:0px; position:abs
-
Do a good job in implementing the Measures for the Supervision and Administration of Online Drug Sales
Time of Update: 2023-01-01
js?cdnversion='+~(-new Date()/36e5)];All provinces, autonomous regions, municipalities directly under the Central Government, and the Drug Administration of the Xinjiang Production and Construction Corps: The Measures for the Supervision and Administration of Online Sales of Drugs (hereinafter referred to as the Measures) were promulgated on September 1, 2022 and came into force on December 1, 2022.
-
The spread of the new crown epidemic in the United States Experts warn that there may be a new peak in the winter
Time of Update: 2023-01-01
The US Centers for Disease Control and Prevention said on the 25th that it is tracking the new subtype XBB of the Omicron strain that has spread in many parts of the United States.
-
On November 29, Chinese medicine stocks were repeatedly active, and many stocks rose to the limit
Time of Update: 2023-01-01
It is reported that previously, Tailong Pharmaceutical issued an announcement that its wholly-owned subsidiary intends to jointly invest with Zhengzhou High-tech Industry Investment Group to establish Longhua Pharmaceutical Industry Fund with a scale of 400 million yuan.
-
Guangshengtang 20cm up limit, Chinese medicine 2 plates... On the 16th, the pharmaceutical sector became active again
Time of Update: 2022-12-30
【Pharmaceutical Network Pharmaceutical Stock Market】 On December 16, the intraday Chinese medicine sector was active again, Guangshengtang hit the 20cm price limit, China Pharmaceutical achieved 2 con
-
Price gouging, bundling? Wenzhou urban interview warns a large number of pharmaceutical companies!
Time of Update: 2022-12-30
In order to ensure the overall order of the epidemic-related pharmaceutical and equipment market during the adjustment and optimization of epidemic prevention and control policies, the Ouhai District
-
The pharmaceutical sector has changed! Lingkang Pharmaceutical, Yisheng Pharmaceutical, etc
Time of Update: 2022-12-30
On the news, Xinhua Pharmaceutical said on the interactive platform on December 21 that the company is actively cooperating with the relevant requirements of the national epidemic prevention policy, working overtime to produce urgently needed drugs in the market and making every effort to ensure market supply.
-
This pharmaceutical stock will be suspended from trading on the 20th due to the acquisition of assets! There have been many unsuccessful reorganizations
Time of Update: 2022-12-30
【Pharmaceutical Network Pharmaceutical Stock Market】Recently, Fengyuan Pharmaceutical issued an announcement that the company is planning to issue shares to purchase assets and raise supporting funds.
-
This 5-day, 3-board pharmaceutical stock was fined more than the company's net profit in the first three quarters because of monopoly
Time of Update: 2022-12-30
News on December 13, Northeast Pharmaceutical announced that the company recently received the "Administrative Penalty Notice" issued by the Liaoning Provincial Administration for Market Regulation, because the company violated the anti-monopoly law by selling L-carnitine APIs at unfairly high prices between November 2018 and June 2019, and the company was fined a total of 133 million yuan.
-
The number of fever outpatient visits in Beijing has increased significantly, and medical service measures have been actively optimized
Time of Update: 2022-12-30
After the optimization and adjustment of epidemic prevention and control policies, a large number of people infected with new coronavirus chose to recover at home, and the number of new crown infections diagnosed in hospitals and the number of nucleic acid tests in the city showed a downward trend, during the same period, the number of fever outpatient visits and flu-like cases increased significantly, and the number of 120 emergency calls increased sharply.
-
Pharmaceutical commercial stocks rebounded and will continue to maintain a rapid growth trend
Time of Update: 2022-12-30
82 billion yuan in the first three quarters of this year (+20%); Achieved net profit attributable to owners of RMB920 million (+12.
82 billion yuan in the first three quarters of this year (+20%); Achieved net profit attributable to owners of RMB920 million (+12.
-
The pharmaceutical stock opened its subscription today and is expected to have a net profit of more than $380 million for the full year
Time of Update: 2022-12-30
90%, and it is expected that the company's net cash flow from operating activities after the virtual conversion of notes to cash will exceed RMB71 billion in 2022, with high profit quality.
